Edgar Filing: Cellular Biomedicine Group, Inc. - Form 8-K

Cellular Biomedicine Group, Inc.

Form 8-K

January 09, 2017

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 9, 2017

CELLULAR BIOMEDICINE GROUP, INC.

(Exact name of registrant as specified in its charter)

Delaware 001-36498 86-1032927

(State or other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)

19925 Stevens Creek Blvd., Suite 100

Cupertino, California

95014

(Address of Principal Executive Offices) (Zip Code)

Registrant's telephone number, including area code: (408) 973-7884

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Edgar Filing: Cellular Biomedicine Group, Inc. - Form 8-K

Item 7.01 Regulation FD Disclosure.

On January 9, 2017, Cellular Biomedicine Group, Inc. (the "Company") issued a press release announcing the commencement of patient enrollment in China for its CALL-1 ("CAR-T against Acute Lymphoblastic Leukemia") Phase I clinical trial utilizing its optimized proprietary C-CAR011 construct of CD19 chimeric antigen receptor T-cell ("CAR-T") therapy for the treatment of patients with relapsed or refractory (r/r) CD19+ B-cell Acute Lymphoblastic Leukemia. A copy of the press release is attached hereto as Exhibit 99.1.

Attached as Exhibit 99.2 to this Current Report is the form of presentation that the Company will be using in connection with its presentation to certain potential investors at the 9th Annual Biotech Showcase conference on January 10, 2017 in San Francisco, California.

Item 9.01. Financial Statements and Exhibits.

- (d) Exhibits
- 99.1 Press Release, dated January 9, 2017
- 99.2 Presentation

Edgar Filing: Cellular Biomedicine Group, Inc. - Form 8-K

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Cellular Biomedicine Group, Inc.

Date: January 9, 2017 By: /s/ Bizuo (Tony) Liu

Bizuo (Tony) Liu Chief Executive Officer